Improving treatment of neurodevelopmental disorders: Recommendations based on preclinical studies
| العنوان: | Improving treatment of neurodevelopmental disorders: Recommendations based on preclinical studies |
|---|---|
| المؤلفون: | Homberg, J. R., Kyzar, E. J., Stewart, A. M., Nguyen, M., Poudel, M. K., Echevarria, D. J., Collier, A. D., Gaikwad, S., Klimenko, V. M., Norton, W., Pittman, J., Nakamura, S., Koshiba, M., Yamanouchi, H., Apryatin, S. A., Scattoni, M. L., Diamond, D. M., Ullmann, J. F. P., Parker, M. O., Brown, R. E., Song, C., Kalueff, A. V. |
| المصدر: | Expert Opin. Drug. Discov. Expert Opinion on Drug Discovery |
| بيانات النشر: | Taylor and Francis Ltd, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | HALOPERIDOL, AMPHETAMINE PLUS DEXAMPHETAMINE, NEUROBIOLOGY, PIMOZIDE, GENOTYPE ENVIRONMENT INTERACTION, PRODROMAL SYMPTOM, TRANSLATIONAL MEDICAL RESEARCH, CLONIDINE, PRIORITY JOURNAL, SEROTONIN UPTAKE INHIBITOR, PHYSIOLOGICAL PROCESS, HERITABILITY, DISEASE MODELS, ANIMAL, NALTREXONE, TRANSLATIONAL RESEARCH, HUMAN, HUMANS, HEREDITY, EPIGENETICS, BIOLOGICAL MARKER, ANIMAL MODELS, PHENOTYPIC VARIATION, DRUG DESIGN, OLANZAPINE, GENETICS, PSYCHOPHARMACOLOGY, MENTAL DISEASE, NEUROIMAGING, PATHOPHYSIOLOGY, BIOMARKERS, METABOLISM, DISEASE MODEL, ZIPRASIDONE, ENDOPHENOTYPE, TREATMENT INDICATION, BUSPIRONE, RISPERIDONE, ADHD, NONHUMAN, REVIEW, STRATEGIC PLANNING, NEUROTRANSMITTER AGENTS, AUTISM, NEURODEVELOPMENTAL DISORDERS, CLINICAL ASSESSMENT, GENETIC ANALYSIS, DRUG DEVELOPMENT, ENVIRONMENTAL ENRICHMENT, LISDEXAMFETAMINE, ENDOPHENOTYPES, NEUROTRANSMITTER, BEHAVIOR CHANGE, ANIMALS, ANIMAL, ATOMOXETINE, METHYLPHENIDATE, DRUG DISCOVERY, ARIPIPRAZOLE, CLINICAL EVALUATION, PROCEDURES, AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS, COMORBIDITY |
| الوصف: | Introduction: Neurodevelopmental disorders (NDDs) are common and severely debilitating. Their chronic nature and reliance on both genetic and environmental factors makes studying NDDs and their treatment a challenging task.Areas covered: Herein, the authors discuss the neurobiological mechanisms of NDDs, and present recommendations on their translational research and therapy, outlined by the International Stress and Behavior Society. Various drugs currently prescribed to treat NDDs also represent a highly diverse group. Acting on various neurotransmitter and physiological systems, these drugs often lack specificity of action, and are commonly used to treat multiple other psychiatric conditions. There has also been relatively little progress in the development of novel medications to treat NDDs. Based on clinical, preclinical and translational models of NDDs, our recommendations cover a wide range of methodological approaches and conceptual strategies.Expert opinion: To improve pharmacotherapy and drug discovery for NDDs, we need a stronger emphasis on targeting multiple endophenotypes, a better dissection of genetic/epigenetic factors or "hidden heritability," and a careful consideration of potential developmental/trophic roles of brain neurotransmitters. The validity of animal NDD models can be improved through discovery of novel (behavioral, physiological and neuroimaging) biomarkers, applying proper environmental enrichment, widening the spectrum of model organisms, targeting developmental trajectories of NDD-related behaviors and comorbid conditions beyond traditional NDDs. While these recommendations cannot be addressed all in once, our increased understanding of NDD pathobiology may trigger innovative cross-disciplinary research expanding beyond traditional methods and concepts. © 2015 2015 Taylor & Francis. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=od_______917::bdb880939927ea5b0d23d488e27a6ecc https://aquila.usm.edu/cgi/viewcontent.cgi?article=18872&context=fac_pubs |
| Rights: | OPEN |
| رقم الانضمام: | edsair.od.......917..bdb880939927ea5b0d23d488e27a6ecc |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |